172 related articles for article (PubMed ID: 36806558)
41. Tumor fragmentation estimated by volume surface ratio of tumors measured on 18F-FDG PET/CT is an independent prognostic factor of diffuse large B-cell lymphoma.
Decazes P; Becker S; Toledano MN; Vera P; Desbordes P; Jardin F; Tilly H; Gardin I
Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1672-1679. PubMed ID: 29705879
[TBL] [Abstract][Full Text] [Related]
42. Prognostic Value of Baseline Radiomic Features of
Lue KH; Wu YF; Lin HH; Hsieh TC; Liu SH; Chan SC; Chen YH
Diagnostics (Basel); 2020 Dec; 11(1):. PubMed ID: 33379166
[TBL] [Abstract][Full Text] [Related]
43. Tumor necrosis at FDG-PET is an independent predictor of outcome in diffuse large B-cell lymphoma.
Adams HJA; de Klerk JMH; Fijnheer R; Heggelman BGF; Dubois SV; Nievelstein RAJ; Kwee TC
Eur J Radiol; 2016 Jan; 85(1):304-309. PubMed ID: 26515992
[TBL] [Abstract][Full Text] [Related]
44. Predictive Significance of a New Prognostic Score for Patients With Diffuse Large B-Cell Lymphoma in the Interim-Positron Emission Tomography Findings.
Kong Y; Qu L; Li Y; Liu D; Lv X; Han J
Medicine (Baltimore); 2016 Feb; 95(6):e2808. PubMed ID: 26871850
[TBL] [Abstract][Full Text] [Related]
45. Comparison of the prognostic values of
Lim CH; Hyun SH; Moon SH; Cho YS; Choi JY; Lee KH
Sci Rep; 2020 Jul; 10(1):12748. PubMed ID: 32728134
[TBL] [Abstract][Full Text] [Related]
46. Intratumor Heterogeneity Assessed by
Lue KH; Wu YF; Liu SH; Hsieh TC; Chuang KS; Lin HH; Chen YH
Acad Radiol; 2020 Aug; 27(8):e183-e192. PubMed ID: 31761665
[TBL] [Abstract][Full Text] [Related]
47. Pretherapy 18F-fluorodeoxyglucose positron emission tomography/computed tomography robust radiomic features predict overall survival in non-small cell lung cancer.
Mostafa R; Abdelsamie Kandeel A; Abd Elkareem M; Nardo L; Abdelhafez YG
Nucl Med Commun; 2022 May; 43(5):540-548. PubMed ID: 35190518
[TBL] [Abstract][Full Text] [Related]
48. Molecular subtype classification of breast cancer using established radiomic signature models based on
Liu J; Bian H; Zhang Y; Gao Y; Yin G; Wang Z; Li X; Ma W; Xu W
Front Biosci (Landmark Ed); 2021 Aug; 26(9):475-484. PubMed ID: 34590460
[No Abstract] [Full Text] [Related]
49. Quantitative Radiomics Features in Diffuse Large B-Cell Lymphoma: Does Segmentation Method Matter?
Eertink JJ; Pfaehler EAG; Wiegers SE; van T; Brug D; Lugtenburg PJ; Hoekstra OS; Zijlstra JM; de Vet HCW; Boellaard R
J Nucl Med; 2022 Mar; 63(3):389-395. PubMed ID: 34272315
[TBL] [Abstract][Full Text] [Related]
50. Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy.
Sjöholm T; Korenyushkin A; Gammelgård G; Sarén T; Lövgren T; Loskog A; Essand M; Kullberg J; Enblad G; Ahlström H
Cancer Imaging; 2022 Dec; 22(1):76. PubMed ID: 36575477
[TBL] [Abstract][Full Text] [Related]
51. Functional Parameters of
Yang J; Zhu S; Pang F; Xu M; Dong Y; Hao J; Ma X
Contrast Media Mol Imaging; 2018; 2018():8659826. PubMed ID: 30363729
[TBL] [Abstract][Full Text] [Related]
52. Prognostic Impact of Pretreatment 2-[
Albano D; Dondi F; Mazzoletti A; Bellini P; Giubbini R; Bertagna F
Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34069203
[No Abstract] [Full Text] [Related]
53. To evaluate prognostic significance of metabolic-derived tumour volume at staging 18-flurodeoxyglucose PET-CT scan and to compare it with standardized uptake value-based response evaluation on interim 18-flurodeoxyglucose PET-CT scan in patients of non-Hodgkin's lymphoma (diffuse large B-cell lymphoma).
Gupta N; Singh N
Nucl Med Commun; 2020 Apr; 41(4):395-404. PubMed ID: 32073552
[TBL] [Abstract][Full Text] [Related]
54. Deep-Learning
Capobianco N; Meignan M; Cottereau AS; Vercellino L; Sibille L; Spottiswoode B; Zuehlsdorff S; Casasnovas O; Thieblemont C; Buvat I
J Nucl Med; 2021 Jan; 62(1):30-36. PubMed ID: 32532925
[TBL] [Abstract][Full Text] [Related]
55. Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer.
Roy S; Whitehead TD; Li S; Ademuyiwa FO; Wahl RL; Dehdashti F; Shoghi KI
Eur J Nucl Med Mol Imaging; 2022 Jan; 49(2):550-562. PubMed ID: 34328530
[TBL] [Abstract][Full Text] [Related]
56. PET-derived tumor metrics predict DLBCL response and progression-free survival.
Islam P; Goldstein J; Flowers CR
Leuk Lymphoma; 2019 Aug; 60(8):1965-1971. PubMed ID: 30714446
[TBL] [Abstract][Full Text] [Related]
57. Prognostic value of interim FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: Systematic review and meta-analysis.
Adams HJ; Kwee TC
Crit Rev Oncol Hematol; 2016 Oct; 106():55-63. PubMed ID: 27637352
[TBL] [Abstract][Full Text] [Related]
58.
Cui Y; Jiang Y; Deng X; Long W; Liu B; Fan W; Li Y; Zhang X
Acad Radiol; 2023 Jul; 30(7):1408-1418. PubMed ID: 36437191
[TBL] [Abstract][Full Text] [Related]
59. Predictive value of F-18 FDG PET/CT quantization parameters in diffuse large B cell lymphoma: a meta-analysis with 702 participants.
Xie M; Wu K; Liu Y; Jiang Q; Xie Y
Med Oncol; 2015 Jan; 32(1):446. PubMed ID: 25511321
[TBL] [Abstract][Full Text] [Related]
60. Methodological Aspects and the Prognostic Value of Metabolic Tumor Volume assessed with 18F-FDG PET/CT in Lymphomas.
Tutino F; Giovannini E; Pastorino S; Ferrando O; Giovacchini G; Ciarmiello A
Curr Radiopharm; 2022; 15(4):259-270. PubMed ID: 35352655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]